CCP Projects and Grants

The majority of our work is funded through the open calls of national and international grant providers such as Ministry of Education, Youth and Sports of the Czech Republic or EU framework programmes. Only major infrastructure funding projects or international cooperation projects are listed here.

We give thanks to all providers for their support.

Current Grants

---

Ministry of Education, Youth and Sports

• MEYS, LUC23175 - Advanced genome editing: Extracellular vesicle in disease modelling and mouse models development, 2023–2026, R. Sedláček [www]
• MEYS, CZ.02.01.01/00/22_010/0007164 - Systemic omics analysis of retinoic acid signaling pathways in vertebrate development, 2023–2027, B. Mrázková [www]
• MEYS, LM2023036 - Czech Centre for Phenogenomics (CCP), 2023–2026, R. Sedláček [www]
• MEYS, CZ.02.01.01/00/23_015/0008189 - Upgrade of the large research infrastructure CCP III, 2024–2026, R. Sedláček [www]

---

Czech Academy of Sciences

• CAS, VP25 Strategie AV21 - Virology and antiviral therapy, 2021–2025, J. Hejnar, R. Sedláček [www]
• CAS, VP29 Strategie AV21 - Towards precision medicine and gene therapy, 2022–2026, R. Sedláček [www]

---

Czech Science Foundation

• GACR, 22-05167S - Perspective application of xenosensor nuclear receptors ligands in therapy of cholestatic liver diseases, 2022–2024, K. Chalupský [www]
• GACR, 22-17139K - SARS-Cov-2: understanding the entry, multi-organ spread and immune response in the context of vaccination and re-infection, 2022–2025, R. Sedláček [www]
• GACR, GA23-04671S - Metabolic switch in liver regeneration, 2023–2025, R. Sedláček [www]
• GACR, 25-17360S - Deciphering cellular and molecular principles of choroid plexus development<br type="_moz" />, 2025–2027, J. Procházka

---

Horizon Europe

• Horizon Europe, 101072427 - GetRadi - Gene Therapy of Rare Diseases, 2022–2026, R. Sedláček [www]
• Horizon Europe, 101046133 - ISIDORe - Integrated Services for Infectious Diseases Outbreak Research, 2022–2025, P. Bartůněk, P. Hozák, R. Sedláček [www]
• Horizon Europe, 101131669 - INFRAPLUS - Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research, 2023–2026, R. Sedláček [www]
• Horizon Europe, 101159096 - TREM2MEDS Towards the clinical implementation of TREM2 MICROglia ENGENEering for treating dementiaS, 2024–2026, R. Sedláček [www]
• Horizon Europe, 101188158 - PRIM-TECH3R INFRAFRONTIER Preclinical in vitro Models for the Replacement, Reduction and Refinement of Mouse Models in Preclinical Studies, 2025–2027, R. Sedláček [www]

---

Ministry of Health

• MH, NU22-05-00374 - Gene engineered killer T cells for the therapy of acute myeloid leukemia, 2022–2025, R. Sedláček [www]
• MH, NU22-08-00160 - Mitochondrial function is essential for liver tumour formation and liver regeneration, 2022–2025, J. Procházka [www]
• MH, NU23-10-00550 - Novel therapeutic approaches in achondroplasia treatment, 2023–2026, J. Procházka [www]

---

Technology Agency of the Czech Republic

• TACR, TN02000132 - New methods of diagnosis, monitoring, treatment, and prevention of genetic diseases (DIAMOD), 2023–2026, R. Sedláček [www]
• TACR, FW10010022 - SpeciAI - Proven methodology using new approaches in x-ray imaging of soft tissues in connection with automated diagnostics, 2024–2026, F. Špoutil [www]

---

Past Grants

• CBR, Smart Akcelerátor II - Improving the promotion of the services of the Czech Centre for Phenogenomics, 2021–2022, R. Sedláček
• MEYS, LM2018126 - Czech Centre for Phenogenomics (CCP), 2020–2022, R. Sedláček [www]
• MEYS, CZ.02.1.01/0.0/0.0/18_046/0015861 - Infrastructure upgrade of CCP II, 2020–2022, R. Sedláček [www]
• Horizon 2020, H2020 - Erasmus+ - EAC/A05/2017 600803 PATHBIO - Precision Pathobiology for Disease Models, 2019–2021, R. Sedláček
• GACR, 19-19025Y - Non-canonical role of ameloblastin in regulation of homeostasis in structural tissues and its potential clinical application, 2019–2021, J. Procházka [www]
• GACR, 19-21696S - Deciphering biological role of ZNF644 to edit the activity of G9a/GLP methylation complex, 2019–2021, R. Sedláček [www]
• MEYS, LTAB19002 - The role of ATF2 transcription factor in development and homeostasis of colon and its involvement in progression of colorectal carcinoma, 2019–2021, J. Procházka [www]
• Horizon 2020, H2020 INFRAEOSC-04-2018, 824087 EOSC-Life - Providing an open collaborative space for digital biology in Europe, 2019–2023, P. Bartůněk, R. Sedláček [www]
• Horizon 2020, H2020, 763823 WIDESPREAD - Advanced Research Incubator in Biosciences (ARIB), 2017–2018, R. Sedláček [www]
• Horizon 2020, H2020 - MSCA-ITN-2017765269 IMGENE - Improving genome editing efficiency, 2017–2021, R. Sedláček [www]
• Horizon 2020, H2020-INFRADEV-2016-1-730879, 730879 INFRAFRONTIER2020 - Towards enduring mouse resources and services advancing research into human health and disease, 2017–2022, R. Sedláček [www]
• CAS, VP18 Strategie AV21 - Preclinical Testing of Potential Pharmaceuticals, 2017–2023, K. Chalupský, R. Sedláček, Š. Suchanová [www]
• MEYS, CZ.02.1.01/0.0/0.0/16_013/0001789 - Upgrade of the Czech Centre for Phenogenomics: developing towards translation research, 2017–2020, R. Sedláček [www]
• CAS, DAAD-17-12 - Defining metabolic functions of ADAM10 in the liver, 2017–2018, K. Chalupský
• CAS, DAAD-17-14 - Role of G-protein signaling in the CX3CR1 chemokine receptor function, 2017–2018, R. Sedláček
• GACR, 17-13491S - Role of NME7 in insulin resistance and related metabolic disturbances, 2017–2019, L. Šedová [www]
• MH, 17-30138A - OXPHOS addiction as a new hallmark in cancer: Its use for development of novel, efficient cancer therapy, 2017–2020, R. Sedláček [www]
• MEYS, LQ1604 - BIOCEV: from Fundamental to Applied Research, 2016–2020, R. Sedláček [www]
• MEYS, LM2015040 - Czech Centre for Phenogenomics, 2016–2019, R. Sedláček [www]
• Horizon 2020, H2020 - IPAD-MD, 653961 IPAD-MD - Research Infrastructures for Phenotyping, Archiving and Distribution of Mouse Disease Models - Promoting International Cooperation and User Engagement to Enhance Biomedical Innovation, 2015–2019, R. Sedláček [www]
• GACR, GA15-24769S - DNA demethylation in the IFNγ signalling pathway modulates tumour progression and tumour-cell interactions with the immune system, 2015–2017, M. Reiniš [www]
• MEYS, CZ.1.05/2.1.00/19.0395 - Higher quality and capacity for transgenic models breeding, 2015–2015, R. Sedláček
• GACR, GA15-23165S - Regulation of heterochromatic gene silencing, 2015–2017, K. Chawengsaksophak [www]
• MEYS, LH14276 LH - KONTAKT II - Novel Causative Genes Identification and Functional Study for selected Mendelian Disorders, 2014–2016, R. Sedláček [www]
• GACR, GA14-10100S - Utilization of novel mouse strains for investigation of the NK cell regulatory role in development and therapy of cancer, 2014–2016, M. Indrová [www]
• FP7 EU, 312325 Infrafrontier-I3 - Development of mouse mutant resources for functional analyses of human diseases - Enhancing the translation of research into innovation, 2013–2016, R. Sedláček [www]
• FP7 EU, 334431 AD PATHOGENESIS - Role of CRMP2 and Pin1 in the pathogenesis of Alzheimers disease, 2013–2017, M. Balaštík [www]
• GACR, GA13-01710S - Reactivity of pulmonary arteries in pulmonary hypertension, 2013–2017, K. Chalupský [www]
• MEYS, OPVK CZ.1.07/2.3.00/30.0050 - Founding the expert platform for phenotyping and imaging technologies, 2013–2015, R. Sedláček, P. Hozák [www]
• MH, NT14461 - Senescence cells elimination in minimal residual tumour disease therapy, 2013–2015, M. Reiniš [www]
• MH, NT14451 - New technology for correction of mutations in monogenetic diseases by targeted reparation of mutations using specific nucleases, 2013–2015, R. Sedláček [www]
• TACR, TA03011057 - Development of new methods to analyze enviromental genotoxic stress and mutagenicity of potential pharmaceutical compounds., 2013–2016, R. Sedláček [www]
• MEYS, 7AMB13AT012 - Structural and functional analysis of interaction between calmodulin and plectin isoform 1a, 2013–2014, M. Gregor [www]
• MEYS, LK11213 LK-NÁVRAT - Analysis of genes Pin1 and CRMP2A and their impact on axon growth, branching and regeneration in vitro and in vivo, 2012–2016, M. Balaštík [www]
• MEYS, LM2011032 INFRAFRONTIER-CZ - Infrafrontier-CZ/Czech Centre for Phenogenomics as a national centre of „The European infrastructure for phenotyping and archiving of model mammalian genomes“: Integration of the Czech national centre into international network, 2012–2015, R. Sedláček [www]
• MEYS, 7E12089 - Czech center INFRAFRONTIER - The European infrastructure for phenotyping and archiving of model mammalian genomes, 2012–2012, RS. Sedláček [www]
• MEYS, OPVK CZ.1.07/2.3.00/30.0027 - Founding the Centre of Transgenic Technologies, 2012–2015, R. Sedláček, V. Kořínek, Z. Kozmík [www]
• FP7 EU, 284501 INFRACOMP - Coordinating the cooperation of the ESFRI project Infrafrontier with the International Phenotyping Consortium (IMPC), 2011–2014, R. Sedláček [www]
• GACR, GAP302/11/2048 - Function of metalloproteinases in colon epithelium and during development of experimental colitis and colon cancer, 2011–2014, R. Sedláček [www]
• MEYS, OPVK CZ.1.07/2.3.00/20.0102 - Founding of an expert team for the Centre for Phenogenomics, 2011–2014, R. Sedláček [www]
• GACR, GAP303/10/2044 - The Impact of a Liver-Specific Deficiency of Growth Factor Sheddase ADAM10 on Liver Development and Pathology, 2010–2013, R. Sedláček [www]
• GACR, GAP305/10/2143 - Generation of mouse models for targeting stellate cells and myofibroblasts in the liver, 2010–2013, R. Sedláček [www]
• GACR, GC301/08/J053 - Mouse models for investigation of biological functions of novel Kazal-type protease inhibitors LEKTI-2 and LEKTI-3, 2008–2010, R. Sedláček [www]
• CAS, IAA500520812 - Investigating the pathologic role of metalloproteinases in liver using transgenic mice with conditional expression of transgenes, 2008–2012, R. Sedláček [www]